Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Astellas profits suffer from generic Prograf By Tracy Staton Aug 2, 2010 10:00am Astellas Pharma, Japan's No. 2 drugmaker, reported an 18.2 percent drop in first-quarter recurring profit, hampered by competition with generic rivals for a mainstay drug. Report